Core Viewpoint - The article discusses the increasing interest of wealthy individuals, particularly Li Ka-shing, in longevity technologies as a means to extend life and combat aging, highlighting significant investments in stem cell research and anti-aging products [6][9][16]. Investment in Longevity Technologies - Li Ka-shing sold his family's stake in Shanghai and Huang Pharmaceuticals for 4.5 billion to invest in Israeli company Pluristem, which specializes in mesenchymal stem cell technology aimed at tissue repair and anti-aging [7][12]. - The investment reflects a broader trend among the wealthy to seek solutions for longevity, with Li Ka-shing's actions seen as a personal and strategic move to enhance his own lifespan [9][13]. Historical Context of Investments - Li Ka-shing has a long history of supporting health and longevity initiatives, including a $40 million donation to UC Berkeley for a biomedical center and $10 million for a genomics innovation program [10][12]. - His investment in the NAD+ anti-aging product tru niagen, which he personally endorsed after experiencing positive effects, illustrates his commitment to longevity research [12][16]. Market Potential - The article emphasizes the vast market potential for longevity technologies, driven by the wealthy's desire for extended life, as exemplified by other tech entrepreneurs pursuing extreme measures for youth [13][15]. - Li Ka-shing's investments are positioned as a strategic bet on the future of regenerative medicine and the commercialization of longevity solutions [16].

Meeting Overview - The fourth supervisory board meeting of Jia Bi You Biotechnology (Wuhan) Co., Ltd. was held on June 9, 2025, with all three supervisors present [1] - The meeting was convened and chaired by Wang Ji, ensuring compliance with relevant laws and regulations [1] Resolutions Passed - The supervisory board approved the adjustment of the asset acquisition and fundraising plan, which involves issuing shares and cash to purchase Shanghai Ouyi Biomedical Technology Co., Ltd. The adjustment includes changes to the performance compensation calculation method and the addition of impairment compensation clauses [1][2] - The board also approved the revised draft of the asset acquisition report and its summary, ensuring compliance with the Securities Law and relevant regulations [2][3] - A supplementary agreement regarding the asset acquisition agreement with certain counterparties was approved [3] - A supplementary agreement concerning performance compensation commitments was also approved [4] - The board confirmed that the transaction complies with the relevant provisions of the Major Asset Restructuring Management Measures [4][5] - The board affirmed that the transaction meets the regulatory requirements for major asset restructuring [4][5] - The board determined that there are no circumstances that would prevent the company from issuing shares to specific targets [5] - The board approved the pro forma financial statements related to the transaction and their review report [5] - Measures to mitigate the dilution of immediate returns from the transaction were also approved [5]

智通财经5月29日电，研究人员日前在美国《科学公共图书馆·生物学》杂志发表的一项最新研究中说， 科学文献正面临被大量基于公开数据、且易于利用人工智能工具处理的误导性生物医学论文淹没的风 险。在这项研究中，来自英国萨里大学等机构的科研人员重点分析了341篇基于美国全国健康和营养调 查的数据的研究论文。全国健康和营养调查是一个开放数据集，收集了数千名美国人的健康、饮食和生 活方式数据。这些论文于2014年至2024年间发表在147份由前沿传媒公司、埃尔斯维尔和施普林格·自然 集团等多家出版商出版的期刊上。 新研究：人工智能或与误导性医学论文数量激增相关 ...

Group 1 - The biomedical precision optical filter developed by Shenyang Institute of Instrumentation Science is a national manufacturing single champion product, crucial for medical diagnostic equipment [1] - The filter allows specific wavelengths of light to pass through, enabling accurate detection of various biomarkers in blood tests through fluorescence detection [1] - The company has achieved breakthroughs in membrane technology, enabling the precise deposition of 200 to 300 layers of thin films [1] Group 2 - Sodium-ion energy storage has emerged as a new competitive field in the province, with Liaoning Xingkong Sodium Battery Co., Ltd. being one of the first companies to research sodium-ion batteries [2] - The company has developed the world's first pilot production line for sodium-ion batteries and is now in the industrial application phase, with plans to explore mobile and island power supply scenarios [2] - The cross-scale nano-measurement equipment from Shenyang Intelligent Robot Innovation Center can achieve extremely high precision detection, with a maximum detection accuracy of one ten-thousandth of a hair's diameter, primarily used in the semiconductor industry [2]

Core Insights - A breakthrough in medical 3D printing has been achieved by a research team from the California Institute of Technology, developing a technology that allows for the in-situ creation of medical implants and customized therapeutic tissues without traditional invasive surgery [1][2] - The new technique, named "Imaging-Guided In-Situ Ultrasound Printing" (DISP), combines focused ultrasound with specially designed "ultrasound ink" to precisely manufacture biomaterials deep within the body, potentially transforming personalized medicine [1][2] Group 1 - The DISP technology utilizes focused ultrasound to trigger a gelation reaction of biological ink, enabling in-situ printing at targeted locations within the body [1] - The "ultrasound ink" consists of biopolymers, imaging contrast agents, and temperature-sensitive liposomes, which can be delivered to deep tissues via injection or catheter [1][2] - An automated ultrasound transducer operates according to a pre-set digital model, generating localized micro-heating to release cross-linking agents, leading to rapid gelation of the ink [1][2] Group 2 - The biological ink used in this technology is highly tunable, allowing for the design of properties such as enhanced conductivity, drug release, tissue adhesion, and even real-time imaging capabilities [2] - Successful experiments demonstrated the printing of drug-loaded functional biomaterials near bladder tumors in mice and in deep muscle tissues of rabbits, showcasing DISP's potential in drug delivery, tissue repair, and bioelectronic device construction [2] - Safety assessments indicated that the technology did not cause significant inflammation or tissue damage, and the gel ink is not naturally cleared by the body within a week, indicating good biocompatibility [2] Group 3 - The biomedical field is a significant application area for 3D printing technology, traditionally involving external printing of patient-matched scaffolds before surgical implantation [2] - The DISP technology addresses the limitations of traditional methods by enabling direct in-body printing of biomaterials, potentially alleviating patient discomfort associated with surgeries [2] - Future advancements, including the integration of artificial intelligence for real-time path planning, may revolutionize the traditional model of constructing and implanting 3D printed biomaterials, further advancing personalized medicine [2]

1.【小鹏汇天"陆地航母"飞行体生产许可证（PC）申请获受理】小鹏汇天5月9日宣布，"陆地航母"飞行体 （代号：X3-F）生产许可证（PC）申请正式获得民用航空中南地区管理局受理，标志着飞行汽车产品量 产体系开始接受局方审查。（财联社） 2.【古尔曼：苹果正为新Mac、智能眼镜和AI服务器开发专用芯片】根据彭博社马克·古尔曼的说法，苹果 正在开发一款专为智能眼镜设计的新型芯片，目标在2026至2027年实现量产，计划未来两年左右推出对 应的智能眼镜产品，与Meta旗下Ray-Ban直接竞争。（搜狐） 3.【纳米3D打印磷酸钙：陶瓷骨移植的新未来】在悉尼大学，由生物医学工程教授兼创新生物工程培训 中心主任Hala Zreiqat领导的研究人员开发了一种3D打印方法，用于制造纳米结构的磷酸钙。（搜狐） 4.【我国首艘深水铺管起重船进入国际市场】驻津央企海洋石油工程股份有限公司旗下的我国首艘深水铺 管起重船——"海洋石油201"船启航，驶向中东区域海管作业现场。这也是该船首次进入国际市场，对提 升我国大型海洋工程船舶国际化运营能力具有重要意义。 "海洋石油 201"船是世界上第一艘同时具备4000吨级重型起重能力、 ...